Atea's second quarter reads as a quiet financial print and a loud clinical one. The first half closed with the bemnifosbuvir/ruzasvir regimen having just cleared its first Phase 3 in chronic hepatitis C - a 93.9% sustained-virologic-response rate versus 94.8% for the standard-of-care Epclusa, on a US/Canadian population chosen to mirror how HCV actually presents in 2026 (concomitant medications in roughly 89% of patients, injection-drug-use route of transmission in 55% or more, comorbid psychiatric diagnoses in roughly two-thirds). Non-inferiority was met within a prespecified 5% margin. The next data point, from the C-FORWARD trial outside North America, is the bigger one and arrives in early Q1 2027. The market opportunity is in the answer to that second question, not in the $32.9 million second-quarter net loss that the income statement leads with. Quarterly operating cash use is running close to $42 million, and the company exited the half with $219.5 million of cash and investments against management's stated "through 2027" runway. The market is pricing the equity at roughly $411 million of equity value (about $5.12 a share, mid-week) on a 52-week band of $2.78-$6.45 - a range that says the market has underwritten the first Phase 3 read but is reserving the second. The open question is whether C-FORWARD extends non-inferiority into the genotypes more common outside the US, and whether the equity can hold the multiple that already prices a successful launch.